Clinical Trial Update: Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and immunogenicity of RSVpreF coadministered with SIIV in adults aged 65 and older; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease

Drugs mentioned

• RSVpreF
• SIIV (seasonal influenza vaccine)

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus | Phase 3 | Status: COMPLETED | Results posted: 2023-10-27